NCT03953326

HeartPhone Cancer Survivors Trial 2019

Digital Intervention to Promote Physical Activity and Improve Cardiovascular Health Among Cancer Survivors

• Status: Terminated
• Phase: Phase 1 / Phase 2
• Study type: Interventional
• Enrollment: 2 (actual)
• Sponsor: Penn State University · Academic / Other
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Not accepted

Summary

This is a behavioral study that will examine changes in physical activity and vascular health in response to a digital tool (app) that will appear on participant's lock screen of their Android phone. Participants will be asked to use this app for 3 months and to wear a Fitbit device continuously throughout the study. Participants will be asked to complete questionnaires, participate in fitness testing and measures of cardiovascular health at 3 months and 6 months after baseline assessments. The hypothesis is that exposure to the app will lead to increased physical activity volume and improved microvessel function.

Conditions

• Breast Cancer
• Leukemia
• Lymphoma

Interventions

Type	Name	Description
BEHAVIORAL	HeartPhone app	Evaluative conditioning (temporally distributed micro-doses presented upon activation of smartphone screen)
DRUG	Acetylcholine	Endothelium-dependent vasodilation is tested with the localized delivery of the neurotransmitter
DRUG	Sodium Nitroprusside	Endothelium-independent vasodilation is tested with the localized delivery of the nitric oxide donor
DRUG	L-Arginine, N2-((4-Methylphenyl)Sulfonyl)-, Methyl Ester	This nitric oxide inhibitor is continuously given during the localized delivery of the endothelium-dependent agonist acetycholine.

Timeline

• Start date: 2019-04-23
• Primary completion: 2020-12-31
• Completion: 2020-12-31
• First posted: 2019-05-16
• Last updated: 2026-02-27
• Results posted: 2026-02-27

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study